|Dr. Michael E. Castagna||CEO & Director||983k||N/A||1977|
|Mr. Steven B. Binder||Chief Financial Officer||674.71k||N/A||1963|
|Mr. Joseph Kocinsky||Chief Technology Officer||642.92k||N/A||1964|
|Dr. David B. Thomson||Exec. VP, Gen. Counsel & Sec.||728.74k||N/A||1967|
|Dr. Stuart A. Tross||Chief People & Workplace Officer||638.38k||N/A||1967|
|Ms. Rosabel Realica Alinaya||VP of Investor Relations & Treasury||N/A||N/A||1961|
|Mr. John F. Bedard||Sr. VP of Worldwide Regulatory Affairs||N/A||N/A||1950|
|Mr. James Patrick McCauley Jr., J.D., M.B.A.||Chief Commercial Officer||N/A||N/A||1966|
|Mr. Alejandro Galindo M.B.A., M.S.||Chief Commercial Officer||N/A||N/A||1972|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MannKind Corporation’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 4; Compensation: 3.